Onconomics RGCC
Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer.
The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. A sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer.
Together, the results of these two testing methods provide scientists and clinicians with a comprehensive breakdown of the most suitable and successful treatments for cancer.
Purpose of the test
Purpose of the test
Onconomics RGCC uses advanced scientific methods to analyse how effective specific therapies and treatments are at treating a patient’s cancer.
Cancer is caused when cells mutate and spread. The key to cancer treatment is identifying and inhibiting (or stopping) these cells from multiplying and spreading.
During the test, scientists effectively expose samples to cancer treatments and therapies, recording how effective they are at targeting the cancer cells. Scientists are specifically searching for cytotoxic drugs (those which effectively kill cancer cells).
Onconomics RGCC can be used by clinicians to identify the combination of cancer treatments that have the greatest chance of success.
Useful information
Useful information
Onconomics RGCC assess the chemosensitivity of anti-cancer drugs at treating a patient’s cancer. Because we are all different, our response to treatments can differ too.
Onconomics RGCC test uses gene expression viability assays to test how the cells respond to specific cancer treatments. Scientists are searching for cytotoxic drugs (those which effectively kill cancer cells).
The results of Onconomics RGCC provide detailed information into how effective a specific therapy or drug will be in treating cancer. The results must be interpreted by a clinician, who will assess the thresholds:
- Over 80% cytotoxicity: The drug targets more than 80% of living cells in the sample, therefore it shows sensitivity.
- Between 35% and 80%: The drug targets 35-80% of living cells in the sample, therefore it shows moderate sensitivity.
- Below 35%: The drug targeted less than 35% of living cells in the sample; therefore, the substance is ineffective. This is known as resistance.
Onconomics RGCC requires 15-25 ml of whole (peripheral) blood, to be sent in a liquid preservative in a 50ml volume Falcon tube. Tissue samples require a minimum of 400mg, sent in the vial provided.
Support and training
Support and training
At RGCC, we provide ongoing training and support for clinicians on how to conduct tests and interpret the results for patients. If you would like more information on how to access, perform or analyse the results of the Onconomics RGCC test, then get in touch today.